Forte Biosciences, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Forte Biosciences amended its non-employee director compensation policy effective April 28, 2026. Annual cash retainers range from $42,500 (base director) to $72,500 (chairman); committee fees add $5,000–$30,000 annually. Equity grants consist of $175,000 initial RSU (3-year vest) and $350,000 annual RSU (1-year vest). Grant values are converted to share count at closing price on grant date; all equity subject to change-of-control acceleration and contingent on stockholder plan approval.
Why this rating
Routine director compensation policy amendment. Cash costs immaterial (~$300k–500k annually for ~5–7 directors). Equity grants represent ~0.2–0.5% annual dilution relative to $157M market cap—standard for public biotech. No material business impact.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.